Fish Based analysis Her-2 at Dr. Essa Lab

Fish Based analysis Her-2 at Dr. Essa Lab

The Fish Based analysis Her-2 at Dr. Essa Lab is a highly specialized molecular diagnostic test designed to detect the amplification of the Human Epidermal Growth Factor Receptor 2 (HER2) gene. Located in Karachi, Pakistan, Dr. Essa Lab is a pioneer in advanced pathology and molecular diagnostics, offering this state-of-the-art test to guide critical therapeutic decisions for cancer patients. The HER2 gene, also known as ERBB2, is located on chromosome 17 and plays a vital role in regulating cell growth, division, and repair. When this gene is amplified, it leads to an overproduction of the HER2 receptor protein on the surface of cells, causing them to grow and divide uncontrollably. This phenomenon is a hallmark of certain aggressive cancers, most notably invasive breast cancer and gastric or gastroesophageal junction adenocarcinomas.

Fluorescence In Situ Hybridization (FISH) is widely recognized as the gold standard for assessing HER2 status. Unlike Immunohistochemistry (IHC), which measures the amount of HER2 protein expressed on the cell surface, FISH directly evaluates the genetic material inside the cell nucleus to count the actual number of HER2 gene copies. This direct genetic assessment provides unparalleled accuracy, particularly in cases where IHC results are borderline or equivocal. By determining the exact amplification status of the HER2 gene, the Fish Based analysis Her-2 at Dr. Essa Lab enables oncologists to tailor highly personalized treatment plans, ensuring that patients who will benefit from targeted anti-HER2 therapies receive them, while sparing others from unnecessary and potentially toxic treatments.

At Dr. Essa Lab, this sophisticated molecular analysis is performed by experienced pathologists and molecular biologists using high-precision fluorescence microscopes and advanced hybridization equipment. The clinical importance of this test cannot be overstated; it is a cornerstone of modern oncology that directly impacts patient survival rates and quality of life. By choosing Dr. Essa Lab, patients and clinicians in Karachi and across Pakistan gain access to reliable, international-standard diagnostic services that form the foundation of effective cancer care.

Clinical Procedure: What to Expect

Patient Preparation

Because the Fish Based analysis Her-2 at Dr. Essa Lab is performed on tissue samples that have already been collected during a biopsy or surgical resection, there is no direct physical preparation required from the patient on the day of the laboratory analysis. However, ensuring the accuracy of the test requires meticulous attention to the handling and submission of the tissue specimen. Patients and healthcare providers should observe the following guidelines:

• Submission of Tissue Blocks: The primary requirement is the submission of the Formalin-Fixed Paraffin-Embedded (FFPE) tissue block containing the tumor specimen. This block must be accompanied by the corresponding Hematoxylin and Eosin (H&E) stained slide.
• Pathology Report: A copy of the original histopathology report must be provided. This report helps the molecular pathologist locate the invasive component of the tumor within the tissue block.
• Fixation Guidelines: For optimal results, the tissue must be fixed in 10% neutral buffered formalin for a minimum of 6 hours and a maximum of 72 hours. Improper fixation can lead to DNA degradation and false-negative or uninterpretable results.
• Clinical History: Provide relevant clinical details, including the primary site of the tumor (e.g., breast, stomach), stage of the disease, and any previous HER2 testing results (such as IHC).
• No Fasting Required: Since the test is performed on an existing tissue specimen, the patient does not need to fast or restrict medications prior to the laboratory processing of the block.

During the Procedure

The laboratory phase of the Fish Based analysis Her-2 at Dr. Essa Lab involves a series of highly controlled molecular steps performed by specialized technologists. The process begins with the preparation of the tissue specimen. Extremely thin sections (typically 4 to 5 micrometers) are cut from the paraffin block and mounted on positively charged glass slides. These slides undergo deparaffinization and rehydration to expose the cellular DNA. Next, a pretreatment step is performed using heat and enzymatic digestion (typically with pepsin) to permeabilize the cell membranes and nuclear envelopes, allowing the fluorescent probes to access the target DNA sequences.

Once the tissue is prepared, a mixture of two fluorescently labeled DNA probes is applied to the slide. The first probe is specific to the HER2 gene locus on chromosome 17 (usually labeled with an orange or red fluorophore), and the second probe is specific to the centromere of chromosome 17 (CEP17, usually labeled with a green fluorophore). The slide is then placed in a co-denaturation chamber where heat is applied to separate the double-stranded target DNA and the probe DNA. This is followed by an overnight hybridization period at a controlled temperature (usually 37°C), during which the probes bind specifically to their complementary sequences on the patient’s DNA.

After hybridization, the slides are washed with a stringent buffer solution to remove any unbound or non-specifically bound probes. The nuclei are then counterstained with DAPI (a blue fluorescent dye) to visualize the nuclear boundaries. Finally, the slide is examined under a high-resolution fluorescence microscope equipped with specialized filters. The pathologist counts the orange (HER2) and green (CEP17) signals in at least 20 non-overlapping, invasive tumor cells. The ratio of HER2 to CEP17 signals is calculated to determine if gene amplification is present. The entire laboratory process is conducted under strict quality control protocols to ensure maximum sensitivity, specificity, and reproducibility.

When is a Fish Based analysis Her-2 Performed?

Invasive Breast Carcinoma Diagnosis

The Fish Based analysis Her-2 at Dr. Essa Lab is routinely performed for all patients newly diagnosed with invasive breast cancer. Determining the HER2 status at the time of initial diagnosis is critical because HER2-positive breast cancers tend to grow and spread more aggressively than HER2-negative cancers. Knowing the HER2 status helps oncologists categorize the breast cancer subtype (e.g., HER2-enriched, luminal B) and formulate an appropriate systemic treatment strategy, which may include chemotherapy combined with HER2-targeted agents.

Equivocal Immunohistochemistry (IHC) Results

One of the most common indications for this test is an equivocal or borderline result (IHC 2+) from an initial immunohistochemistry test. While IHC is a cost-effective screening tool that measures protein expression, it can yield ambiguous results due to variations in tissue fixation or staining techniques. In such cases, the Fish Based analysis Her-2 is utilized as the definitive reflex test. Because FISH directly measures gene copy numbers rather than protein levels, it resolves the ambiguity and provides a clear, binary answer (amplified or non-amplified) to guide clinical decision-making.

Gastric and Gastroesophageal Junction Adenocarcinoma

In addition to breast cancer, the Fish Based analysis Her-2 is indicated for patients diagnosed with advanced, recurrent, or metastatic adenocarcinoma of the stomach or gastroesophageal junction. HER2 overexpression occurs in approximately 10% to 20% of these gastric cancers. Identifying HER2 amplification in these patients is clinically significant because it qualifies them for targeted therapy with trastuzumab in combination with standard chemotherapy, which has been shown to significantly improve overall survival and progression-free survival.

Recurrent or Metastatic Cancer Evaluation

Cancer cells can evolve over time, and the HER2 status of a metastatic lesion or recurrent tumor may differ from that of the primary tumor—a phenomenon known as receptor discordance. Therefore, physicians frequently request a Fish Based analysis Her-2 on biopsy samples from metastatic sites (such as the liver, lungs, or bones) or recurrent tumors. This ensures that the patient’s current treatment is aligned with the biological characteristics of the active disease, preventing the missed opportunity for targeted therapy.

Monitoring and Targeted Therapy Selection

Oncologists request this test to identify patients who are candidates for specific FDA-approved anti-HER2 targeted therapies, such as trastuzumab, pertuzumab, ado-trastuzumab emtansine (T-DM1), and lapatinib. These therapies specifically target and inhibit the HER2 receptor, blocking the signaling pathways that drive tumor growth. Conversely, identifying a non-amplified (HER2-negative) status is equally important, as it spares patients from the cardiac toxicities and financial burdens associated with anti-HER2 therapies when they would derive no clinical benefit.

What Does a Fish Based analysis Her-2 Detect?

The Fish Based analysis Her-2 at Dr. Essa Lab is designed to detect and quantify specific genetic parameters within the nuclei of tumor cells. The primary findings and parameters evaluated during this molecular analysis include:

• HER2 Gene Copy Number: The average number of HER2 gene signals observed per tumor cell nucleus.
• CEP17 Copy Number: The average number of centromere 17 signals observed per tumor cell nucleus, which serves as an internal control.
• HER2 to CEP17 Ratio: The mathematical ratio calculated by dividing the total number of HER2 signals by the total number of CEP17 signals across the evaluated cells.
• Gene Amplification: A state where the HER2 gene is replicated excessively, defined by a ratio of ≥ 2.0 or an average HER2 copy number of ≥ 6.0.
• Non-Amplification: A normal genetic state where the HER2 gene is not amplified, defined by a ratio of < 2.0 and an average HER2 copy number of < 4.0.
• Equivocal Genetic Status: Borderline cases that require further evaluation or counting of additional cells.
• Polysomy 17: An increase in the number of chromosome 17 copies per cell (average CEP17 ≥ 3.0), which can mimic HER2 amplification on IHC but represents a different biological state.
• Monosomy 17: A loss of one copy of chromosome 17 per cell (average CEP17 < 1.5), which can artificially elevate the HER2/CEP17 ratio.
• Intratumoral Heterogeneity: The presence of distinct sub-populations of tumor cells with differing HER2 amplification statuses within the same specimen.
• Co-amplification: Simultaneous amplification of the HER2 gene and other adjacent genetic loci on chromosome 17.
• Nuclear Morphology: The structural appearance of the tumor cell nuclei, ensuring that only viable, intact nuclei are evaluated.
• Signal Quality: The brightness, sharpness, and distinctness of the fluorescent signals, which are critical for accurate counting.
• Background Fluorescence: The level of non-specific background staining, which must be minimal to prevent false signal counts.
• Tissue Autofluorescence: Natural tissue glow that must be managed using appropriate optical filters.
• Probe Hybridization Efficiency: The percentage of cells showing successful binding of both HER2 and CEP17 probes.
• Artifact Presence: Identification of tissue folds, dust particles, or probe precipitation that could interfere with signal interpretation.
• Tumor Cell Percentage: Verification that the area evaluated under the fluorescence microscope contains a sufficient density of invasive tumor cells.
• Positive Control Verification: Confirmation that the control slides run alongside the patient sample show expected amplification patterns.
• Negative Control Verification: Confirmation that the negative control slides show normal, non-amplified patterns.
• DAPI Counterstain Integrity: Uniform blue staining of all nuclei, ensuring proper visualization of nuclear boundaries.
• Atypical Signal Patterns: Overlapping signals, clustered signals, or diffuse patterns that require specialized interpretation by the pathologist.
• Gene Deletion: Rare cases where the HER2 gene copy number is significantly lower than normal.
• Technical Adequacy: Overall assessment of whether the slide preparation meets the stringent criteria for clinical reporting.

Turnaround Time and Report Access at Dr. Essa Lab

Dr. Essa Lab is committed to providing timely and highly accurate diagnostic reports, recognizing that treatment decisions for cancer patients are time-sensitive. The turnaround time for the Fish Based analysis Her-2 is typically within 7 to 10 working days. This timeframe is necessary to accommodate the meticulous laboratory steps, including tissue sectioning, overnight hybridization, stringent washing, fluorescence microscopy evaluation, and multi-level pathologist review.

Once the analysis is complete and verified by a consultant molecular pathologist, the report is immediately uploaded to the secure online portal of Dr. Essa Lab. Patients and referring oncologists can access and download the digital report from the official website using the unique lab ID and password provided on the receipt. Additionally, physical copies of the report can be collected from any of the numerous Dr. Essa Lab collection centers located across Karachi and other major cities in Pakistan. The report includes detailed quantitative data, including the average HER2 copy number, average CEP17 copy number, the calculated ratio, and a definitive clinical interpretation accompanied by representative fluorescence images when appropriate.

Fish Based analysis Her-2 Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HER2/CEP17 Ratio	Ratio < 2.0 (Non-amplified)	Ratio ≥ 2.0 (Amplified)
Average HER2 Copy Number	< 4.0 signals per cell	≥ 6.0 signals per cell (Amplified) or 4.0–5.9 (Equivocal)
Average CEP17 Copy Number	1.5–2.9 signals per cell (Normal diploid state)	≥ 3.0 (Polysomy 17) or < 1.5 (Monosomy 17)
Gene Amplification Status	Negative (No HER2 gene amplification detected)	Positive (HER2 gene amplification present)
Signal Pattern	Two distinct orange (HER2) and two green (CEP17) signals per nucleus	Clusters of orange signals (high-level amplification) or multiple green signals
Intratumoral Heterogeneity	Uniform cell population with consistent gene copy numbers	Coexistence of amplified and non-amplified cell populations within the same tumor
Nuclear Integrity	Intact, well-defined nuclear boundaries with uniform DAPI staining	Fragmented, overlapping, or poorly stained nuclei (may require resampling)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Fish Based analysis Her-2?

• Experienced Healthcare Professionals: Our molecular pathology department is led by highly qualified consultant pathologists with extensive training in cytogenetics and molecular oncology.
• Patient-Focused Care: We prioritize patient comfort and clarity, providing comprehensive support throughout the testing process.
• Quality Diagnostic Services: Dr. Essa Lab is committed to international standards of quality, utilizing rigorous internal and external quality control programs.
• Professional Reporting: Reports are detailed, clear, and include all quantitative parameters required by oncologists to make informed treatment decisions.
• Modern Diagnostic Approach: We utilize advanced fluorescence hybridization equipment and high-resolution imaging systems to ensure maximum accuracy.
• Comfortable Environment: Our collection centers across Karachi are designed to provide a professional, clean, and welcoming environment for patients and their families.
• Convenient Location: With an extensive network of branches throughout Karachi and Pakistan, sample submission is easy and highly accessible.
• Commitment to Accurate Diagnosis: Since 1987, Dr. Essa Lab has built a legacy of trust, delivering reliable diagnostic services that healthcare providers depend on.